Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal

Executive Summary

CEO Heather Bresch defended her company’s controversial decision to raise the price of the allergy medicine to $600 during the Forbes Healthcare Summit and even took questions from fellow pharma insiders like “Why did you ruin it?”

You may also be interested in...



Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It

Bipartisan effort seems more focused on increasing cost transparency for US health care services, but stakeholders still are expected to raise drug pricing issues.

J&J Outlines Pricing Transparency Plan, Will Others Follow?

CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.

Pharma’s Pricing Debate Splinters As US Political Confrontation Looms

Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel